Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESPITE: Riociguat Switching in PAH
NCT02007629Phase 3Completed
- Sponsor
- Bayer
- Start
- Feb 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of riociguat in pulmonary arterial hypertension (PAH), sponsored by Bayer. Started Feb 2014; status: completed.
02
Drugs
riociguat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02007629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02007629.